Risk factors

NextBoat is exposed to seasonal and macroeconomic fluctuations in the luxury yacht and boat sales market. The company relies heavily on floorplan financing, manufacturer dealer agreements, and supply channels including repossessions. Intellectual property protection is limited due to a lack of formal patents and copyrights.

NexPoint Diversified Real Estate Trust added risks concerning new tax legislation, social media exposure, and internal controls.

Internal control weaknesses persist regarding journal entry approvals and super user system access for accounting staff.

NextPlat faces significant ongoing net losses and reliance on a single pharmaceutical supplier for 98% of purchases. The company struggles with Nasdaq listing compliance, prompting plans for a reverse stock split. Macroeconomic pressures and inflation continue to threaten profit margins and operating costs.

Nexentis now emphasizes MitoCareX’s preclinical oncology pipeline, unproven MITOLINE™ algorithm, and no commercial products or revenue.

Revenue expanded sharply from $1.80 million to $11.61 million, while operating cash flow remained negative and expenses rose substantially.

OBAI faces severe customer concentration with two customers providing 51.20% and 14.34% of 2025 revenue. Losses reached $10,549,000 in 2025 alongside a history of operating deficits. Founder Doron Kempel and insiders control 95.76% of voting power as a controlled company.

Omeros achieved FDA approval for YARTEMLEA in December 2025, shifting its primary business focus to commercial execution.

The company highlights ongoing internal control weaknesses and delayed SEC filings that trigger litigation and delisting risks.

The company added significant debt through $6.0 million in Senior Secured Notes and shifted a portion of proceeds into digital assets like Bitcoin and Ethereum, introducing extensive crypto-related operational and custody risks.

Customer concentration is high with three customers accounting for 48% of revenues in 2025. Insider ownership is dominant, with Mr. Kapoor holding 83% of common stock. Capital needs are significant for R&D in advanced manufacturing and facility expansion.

OSTX focuses on clinical development of OST-HER2 for rare Osteosarcoma, facing patient enrollment hurdles and capital constraints.